|
|
|
|
|
|
|
Medical Pharmacology Chapter 16: Pharmacology of Antipsychotics Drugs
|
|
|
|
|
|
|
Second Generation Antipsychotic Medications
Case Study 1: The Metabolic Dilemma
Patient: Mr. A., a 34-year-old male with a 10-year history of schizophrenia.
Presentation: Mr. A. has been maintained on olanzapine 20 mg/day for the past 3 years with good control of his psychotic symptoms with no hospitalizations, minimal positive symptoms, and improved social functioning.
However, at his annual physical, he is found to have a BMI of 36, fasting glucose of 128 mg/dL (consistent with prediabetes), LDL of 164 mg/dL, and blood pressure of 138/88 mmHg.
He has gained 28 pounds over 3 years. His psychiatrist considers switching antipsychotics.
Discussion Questions:
1. What is the metabolic risk profile of olanzapine, and how does it compare to other SGAs per the evidence of Newcomer (2005) and the ADA/APA Consensus (2004)?
2. If the team considers switching Mr. A. to a metabolically neutral agent, which options would be appropriate, and what risks does switching introduce?
3. How should the metabolic abnormalities be managed irrespective of the antipsychotic decision?
Teaching Points:
This case illustrates the central clinical tension between psychiatric stability and metabolic safety.
Olanzapine occupies the highest metabolic risk tier alongside clozapine.7,8
Switching to ziprasidone or aripiprazole offers metabolic advantages, but antipsychotic switches carry a meaningful relapse risk, particularly in patients who are psychiatrically stable.
Evidence supports a slow, cross-taper approach with close monitoring.
Regardless of the switching decision, the metabolic syndrome components warrant lifestyle counseling and consideration of lipid-lowering and antihypertensive therapy, consistent with standard cardiovascular risk management.
Case Study 2: Treatment Resistance and Clozapine Initiation
Patient: Ms. B., a 27-year-old woman with schizophrenia, paranoid type, first hospitalized at age 22.
Treatment History: Ms. B. has been trialed on risperidone 6 mg/day (6 weeks, adherence confirmed by blister packs and plasma levels) showing a partial response with persistent auditory hallucinations and paranoid delusions.
She was then switched to aripiprazole 30 mg/day for 10 weeks with adherence verified and reponded with a similar partial response.
A trial of quetiapine 600 mg/day was initiated, but discontinued after 8 weeks due to intolerable weight gain and sedation without meaningful symptom improvement.
She has now been hospitalized for the third time in 5 years.
Current State: On admission, she is acutely psychotic with prominent command auditory hallucinations. She has expressed passive suicidal ideation on prior admissions.
Discussion Questions:
1. Does Ms. B. meet criteria for treatment-resistant schizophrenia? What are the diagnostic requirements, and are they satisfied here?
2. What pharmacological intervention is indicated, and what is the evidentiary basis for this recommendation?
3. What monitoring is required before and during initiation of this therapy, and what adverse effects require particular vigilance?
4. How does Ms. B.'s history of suicidal ideation influence the treatment choice?
Teaching Points:
Ms. B. has failed three antipsychotic trials of different classes at adequate doses and durations with verified adherence and therefore she meets standard criteria for treatment-resistant schizophrenia.
Clozapine is the evidence-based treatment of choice, supported by Kane et al. (1988)4 and confirmed by network meta-analyses.12,13
Her history of suicidal ideation also supports clozapine
This history has a unique FDA indication for reducing suicidal behavior (Meltzer et al., 2003).6
REMS enrollment no longer required (2025), with Absolute Neutrophil Monitory (ANC) monitoring still recommended.
Baseline ECG and metabolic panel are essential
given clozapine's myocarditis risk (greatest in month 1) and its
high metabolic burden.
|
|
|
|
|
|
 |
|
DISCLAIMER
|
